As gene therapies continue to evolve as a promising frontier in medical treatment, regulatory scrutiny intensifies following safety concerns. Recent developments with Sarepta Therapeutics Inc (NASDAQ:SRPT) highlight the delicate balance between innovation and patient safety in the biopharmaceutical industry.
On Monday, the U.S. Food and Drug Administration (FDA) recommended lifting the voluntary hold on Sarepta’s gene therapy for Duchenne Muscular Dystrophy.
